ABSTRACT t(11;14) (q13;q32) occurs in approximately 15%–25% of multiple myeloma (MM) cases and has traditionally been regarded as a standard cytogenetic risk factor. However, recent evidence suggests that MM with t(11;14) exhibits heterogeneous biological characteristics and clinical outcomes distinct from those associ...
T. Tsukamoto, Yuji Shimura, S. Mizutani et al.· Cancer Science· 0 citations
The present retrospective multicenter study in Japan evaluated the role of venetoclax plus azacitidine (V/A) before first allogeneic hematopoietic stem cell transplantation (SCT) in 144 transplant-eligible acute myeloid leukemia (AML). Thirty-seven patients received V/A prior to SCT, mainly as salvage therapy for refra...
Hiroyuki Muranushi, J. Kanda, Tadakazu Kondo et al.· Clinical Hematology Internat...· 0 citations
Background Conventional antibody discovery approaches that do not account for enrichment-driven biases, such as epitope immunogenicity, PCR amplification bias, or protein expression efficiency, may result in under-representation of rare yet functionally relevant clones, necessitating labor-intensive in vitro screening...
Tomoki Iemura, T. Kitawaki, R. Maeda et al.· Journal for ImmunoTherapy of...· 0 citations
This review examines molecular determinants of RS tolerance, focusing on human T-cell leukemia virus type 1-mediated adult T-cell leukemia/lymphoma (ATL) as a model of virus-mediated rewiring of DNA damage responses.
It is demonstrated that SLF2 and SMC5 dysfunction drives premature HSC aging, bone marrow failure, and predisposition to MDS, revealing Atelis Syndrome as a previously unrecognized IBMFS.
Sho Shibata, K. Chonabayashi, Hirofumi Nakamura et al.· Leukemia· 1 citation
These findings suggest the safety and potential efficacy of allogeneic iPSC-PLTs in humans, and are reported the world’s first clinical evaluation of an allogeneic iPSC-PLT product.
Kazumasa Takao, Yoshihiro Kumagae, J. Kanda et al.· Stem Cells Translational Med...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
